MMP-1及TIMP-1在肠粘连组织中的表达及意义
|
摘要
【目的】通过大鼠肠粘连动物模型,检测MMP-1和TIMP-1在肠粘连组织及正常组织中的表达,研究MMP-1和TIMP-1在肠粘连发病中的作用。
【方法】选取SD雄性大鼠70只分为3组,随即取10只作为正常组,观察组30只刮伤其回肠浆膜,创面滴无水酒精,钳夹盲肠系膜动脉制成损伤性肠粘连模型。对照组30只大鼠与模型组一样麻醉、开腹,但不动肠组织,直接关腹。分别于造模后第2天、7天、14天3个时相点各取10只大鼠,处死并分别取小肠浆膜层浆膜粘连面组织,应用免疫组化和图像分析的方法测定粘连组织中MMP-1和TIMP-1在肠粘连组织及正常肠组织中的蛋白表达。
【结果】1、造模术后2天组,观察组中MMP-1和TIMP-1的含量均升高,与正常对照组相比差异有显著性(P＜0.01),MMP-1升至峰值。2、造模术后7天组,观察组中MMP-1含量降低;而TIMP-1的含量升高至峰值,与术后2天组相比差异有显著性(P＜0.01);造模术后7天组与对照组相比差异亦有显著性(P＜0.01)。3、造模术后14天组,观察组中MMP-1、TIMP-1的含量均下降,与术后7天组相比差异有显著性(P＜0.01);造模术后14天组与术后2天组相比差异有显著性(P＜0.01);造模术后14天组与对照组相比差异有显著性(P＜0.01)。4、各时相点模型组与对照组相比均有显著差异(P＜0.01)。5、对照组中两两比较,无显著性差异,(P＞0.05)。
【结论】MMP-1、TIMP-1的活性变化是肠粘形成的重要调节因素之一。
Objective: Through the big mouse intestinal adhesion animal model, examines MMP-1 and TIMP-1 in the intestinal adhesion organization and Normal tissue's expression, studies MMP-1 and TIMP-1 in the intestinal adhesion morbidity function.
Method: Selects SD male gender big mouse 70, zhey were randomly allocated to three groups, Then take 10 rats as a normal group, the observation group was 30 rats with postoperative intestinal adhesion, the injured area drop dehydrated alcohol, the pliers clamps the blind arteria mesenterica to make the damage intestinal adhesion model. The control group 30 big mice and the model group same anaesthesias, operate the abdomen, but motionless intestines organization, direct pass abdomen. Separately after the postoperation 2d, 7d, 14d 3 phase takes 10 big mice respectively, they were sacrificed respectively. Take adhesive tissue of small intestine respectively, the expression of MMP-1 and TIMP-1 in the intestinal adhesive tissues and the normal intestinal tissues were determined by immunohistochemistry assay and image analysis.
Results: 1, makes the mold technique latter 2 day of groups, MMP-1 and the TIMP-1 content exceptionally elevates, compares the difference with the normal control group to have the significance (P<0.01), MMP-1 climbs to the peak value. 2. makes the mold technique latter 7 day of groups, in the organization the MMP-1 content reduces; But the TIMP-1 content elevates to the peak value, compares the difference with the technique latter 2 day of groups to have the significance (P<0.01); Makes the mold technique latter 7 day of groups and the control group compares the difference also to have the significance (P<0.01). 3. makes the mold technique latter 14 day of groups, in the organization MMP-1 and TIMP-1 content drops, compares the difference with the technique latter 7 day of groups to have the significance (PO.01); Makes the mold technique latter 14 day of groups and the technique latter 2 day of groups compares the difference to have the significance (P<0.01); Makes the mold technique latter 14 day of groups and the control group compares the difference to have the significance (P<0.01).4. Each time point model group compared with the control group were significantly different (P <0.01).5. Each other in the control group showed no significant differenceT (P> 0.05).
Conclusion: The MMP-1/ TIMP-1/ active change is one which of important adjustment factors in the intestines stick form.
【方法】选取SD雄性大鼠70只分为3组,随即取10只作为正常组,观察组30只刮伤其回肠浆膜,创面滴无水酒精,钳夹盲肠系膜动脉制成损伤性肠粘连模型。对照组30只大鼠与模型组一样麻醉、开腹,但不动肠组织,直接关腹。分别于造模后第2天、7天、14天3个时相点各取10只大鼠,处死并分别取小肠浆膜层浆膜粘连面组织,应用免疫组化和图像分析的方法测定粘连组织中MMP-1和TIMP-1在肠粘连组织及正常肠组织中的蛋白表达。
【结果】1、造模术后2天组,观察组中MMP-1和TIMP-1的含量均升高,与正常对照组相比差异有显著性(P＜0.01),MMP-1升至峰值。2、造模术后7天组,观察组中MMP-1含量降低;而TIMP-1的含量升高至峰值,与术后2天组相比差异有显著性(P＜0.01);造模术后7天组与对照组相比差异亦有显著性(P＜0.01)。3、造模术后14天组,观察组中MMP-1、TIMP-1的含量均下降,与术后7天组相比差异有显著性(P＜0.01);造模术后14天组与术后2天组相比差异有显著性(P＜0.01);造模术后14天组与对照组相比差异有显著性(P＜0.01)。4、各时相点模型组与对照组相比均有显著差异(P＜0.01)。5、对照组中两两比较,无显著性差异,(P＞0.05)。
【结论】MMP-1、TIMP-1的活性变化是肠粘形成的重要调节因素之一。
Objective: Through the big mouse intestinal adhesion animal model, examines MMP-1 and TIMP-1 in the intestinal adhesion organization and Normal tissue's expression, studies MMP-1 and TIMP-1 in the intestinal adhesion morbidity function.
Method: Selects SD male gender big mouse 70, zhey were randomly allocated to three groups, Then take 10 rats as a normal group, the observation group was 30 rats with postoperative intestinal adhesion, the injured area drop dehydrated alcohol, the pliers clamps the blind arteria mesenterica to make the damage intestinal adhesion model. The control group 30 big mice and the model group same anaesthesias, operate the abdomen, but motionless intestines organization, direct pass abdomen. Separately after the postoperation 2d, 7d, 14d 3 phase takes 10 big mice respectively, they were sacrificed respectively. Take adhesive tissue of small intestine respectively, the expression of MMP-1 and TIMP-1 in the intestinal adhesive tissues and the normal intestinal tissues were determined by immunohistochemistry assay and image analysis.
Results: 1, makes the mold technique latter 2 day of groups, MMP-1 and the TIMP-1 content exceptionally elevates, compares the difference with the normal control group to have the significance (P<0.01), MMP-1 climbs to the peak value. 2. makes the mold technique latter 7 day of groups, in the organization the MMP-1 content reduces; But the TIMP-1 content elevates to the peak value, compares the difference with the technique latter 2 day of groups to have the significance (P<0.01); Makes the mold technique latter 7 day of groups and the control group compares the difference also to have the significance (P<0.01). 3. makes the mold technique latter 14 day of groups, in the organization MMP-1 and TIMP-1 content drops, compares the difference with the technique latter 7 day of groups to have the significance (PO.01); Makes the mold technique latter 14 day of groups and the technique latter 2 day of groups compares the difference to have the significance (P<0.01); Makes the mold technique latter 14 day of groups and the control group compares the difference to have the significance (P<0.01).4. Each time point model group compared with the control group were significantly different (P <0.01).5. Each other in the control group showed no significant differenceT (P> 0.05).
Conclusion: The MMP-1/ TIMP-1/ active change is one which of important adjustment factors in the intestines stick form.
引文
1.Liakakos T,Thomakos N,Fine PM,Dervenis C,Young RL.Peritoneal adhesions:etiology,pathophysiology,and clinical significance.Recent advances in prevention and management.Di Surg 2001;18:260-273.
2.Menzies D,Ellis H.Intestinal obstruction from adhesions-how big is the problom?Ann R Coll Surg Engl 1990;72:60-63.
3.Ghosh AK.Factors involved in the regularion of type Ⅰ collagen gene expression:implication in fibrosisl[J]Exp Hiol Med(May-wood),2002,227(5):301-314.
4.何刚,刘生光,刘金新.凡丁糖预防腹膜粘连抑制胶原基因表达的实验研究[J].蚌埠医学院学报,2003,28(6):474-477.
5.Nagler A,Rivkind AI,Raphael J,et al.Halofuginone-an inhibi-tor of collagen type Ⅰ synthesis-prevents postoperative for-marion ofabdominal adhesions[J].Ann Su 1998,227(4):575-582.
6.袁发焕.MMPs、TIMPs与肾脏疾病.国外医学、泌尿系统分册1999,19(3):105.
7.Clegg PD,Burke RM,Coughlan AR,et al.Characterization of equine matrix metaIlo Droteinase2 and 9,and identification of the cellular sources of these enzymesin in joints.E--qine vet,1997,29:335-342.
8.Brand K.Cncer gene therapy with tissue inhibitors of metalloproteinase(TIMPs)[J].Curr GeneTher,2002:2(2):255.
9.Bassiouny HS.Song RH,HongXF,et al.Flow regulation of 72-kD eollagenase Ⅳ after experimental aterial injury.Circulation,1998,98:157-163.
10.Zhang B,wan MB,Wang LT,et al Expression of TIMP-1 and TGF-beta(1)mRNA in hepatic fibrosis rats and the therapeutic effects of Bushen Rougan Recipe 1[J]Zhong Xi Yi Jie He Xue Bao,2004,2(4):274-277.
11.Singh KP,Gerard HC,Hudson AP,et al.Dynamics of collagen MMP an d TIMP gene expression during the gran ulomatous,fi-brotic process induced by Schistosoma mansoni eggs[J].Ann Trop Med Parasitol,2004,98(6):581-593.
12.Menzies D.Peritoneal adhesions.Incidence,cause,and prevention.Surg Annu 1992;24(Pt 1):27-45.
13.Scott-Coombes D,Whawell S,Vipond MN,Thompson J.Human intraperitoneal fibrinolytic response to elective surgery.Br J Surg 1995;82:414-417.
14.Hellebrekers BW,Trimbos-Kemper GC,Bakkum EA,Trimbos JB,Declerck PJ,Kooistra T,Emeis JJ.Short-term effect of surgical trauma on rat peritoneal fibrinolytic activity and its role in adhesion formation.Thromb Haemost 2000;84:876-881.
15.Chegini N,Kotseos K,Bennett B,Diamond MP,Holmdahl L,Burns J.Matrix metalloproteinase(MMP-1) and tissue inhibitor of MMPin peritoneal fluids and sera and correlation with peritoneal adhesions.Fertil Steril 2001;76:1207-1211.
16.尚晓滨,吴成中,李东华,等.活血化瘀中药对清解通下中药增效作用的实验研究Ⅴ-粘连组 织中MMP-1和TIMP-1影响的实验研究.中国中西医结合外科杂志,2006,12(4):387.
1.Sato H,Takino T,Okada Y,et al.A matrix metalloproteinase expressed on the surface of invasive tumour cells[J].Nature,1994,370(6484):61-65.
2.Edwards DR,Beandry PP,Laing TD,et al.The roles of tissue inhibitors of metalloproteinases in tissue remodeling and cell growth[J].Int J of Obesity,1996,sg-s15,20 Suppl.
3.K1einer D,Stetler-Stevenson WG.Matrix metalloproteinase and metastasi[J].Cancer Chemother Phamacol,1999;43(suppl):42.
4.Brand K.Cncer gene therapy with tissue inhibitors of metalloproteinase(TIMPs)[J].Curr GeneTher,2002:2(2):255.
5.Springman E B,Angleton E L,Bikedalhansen H,et al Multiple modes of activation of latent human fibroblast collagenase evidence for the role of a cys-73 active-site zinc complex in latency and a cysteine swith mechanism for active ion[J].Proceedings of The National Academy of Sciences of The United States of America,1990;87(1):364-368.
6.Morgunova E,Tuuttila A,Bergmann U,et al.Structure of human pro-matrix metalloproteinase-2:active ion mechanism revealed[J].Science,1999;284(5420):1667-1670.
7.Sang Q X,Birkedal-Hansen H,Van Wart H E.Proteolytic and non-proteolytic Activation of human neutrophil progelatiase B[J].Biochimica and 8iophysica Acta,1995:1251(2):99-108.
8.Marcotte P A,Kozan I M,Dorwin S A,et al.The matrix metalloproteinase pump-1catalyzes formation of low-molecular-weight(?) urokinase in cultures of normal human kidney cells[J].Journal of Biological Chemistry,1992;267(20):13803-13806.
9.Edwards DR,Beandry PP,Laing TD,et al.The roles of tissue inhibitors of metalloproteinases in tissue remodeling and cell growth[J].Int J of Obesity,1996,S9-S15,20 Suppl.
10.Vaalamo M,Leivo T,Sarialho-kere U.Differential expression of tissue inhibitors of metalloproteinases(TIMP-1,2,3,and -4) in normal and aberrant wound healing[J].Hum Pathol,1999,30(7):795-802.
11.DeClerck YA,Dartll MI,Eeckhout Y,et al.Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2(TIMP-2)[J].Gene,1994,139:185-191.
12.Gaire M,Magbanul Z,McDonnell S,et al.Structure and expression of the human gene for the matrix metalloproteinase matrillysin[J].J Biol Chem,1994,269:2032-2040.
13.邵彬,聂青和.基质金属蛋白酶组织抑制剂(TIMPs)的基础及临床研究现状[J];实用肝脏病杂志:2005年03期.
14.李敬安,任星峰,等.慢性乙型肝炎肝组织Ⅰ,Ⅲ型胶原及MMP、TIMP的表达[J]中国医师 进修杂志:2006;5.
15.张健珍,龙英姿,等.慢性乙型肝炎血清MMP-1和TIMP-1与肝脏炎症及肝纤维化的相关性;中国实用内科杂志:2007年19期.
16.Kikkawa F,Nawa A,Tamakoshi S,et al.Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the ovary.Cancer,1998,82(11):2249-2255.
17.Tamakoshi K,Kikkawa F,Maeda O,et al.Hyaluronidase activity in gynaecological cancer tissue with different metastatic forms[J].Br J Cancer,1997,75:1807-1811.
18.Inoue Y,AbeK,ObataK,etal.Immunohistochemical Studies on matrixmetall oproteinase-2 MMP-9 and type Ⅳ collage in endometrial carcinoma J.J Obstet Gynecol Res,1997,23:139-145.
19.Davidson B,Goldberg I,Kopolvic J,et al.MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma a clinicopathologic study using immunohistochemistry and mRNA in situhybridization.Gynecol Oncol,1999,73(3):372-382.
20.Sang QX.Complex role of matrix metalloproteinases in angiogenes[J].Cell Res,1998,8(3):171-177.
21.Kim I,Kim HG,Moon SO,et al.Angiopoietin-1 induces endothe-lial cell sprouting through the activation of focal adhesion kinase and plasmin secretion[J].Circ Res,2000,86(9):952-959.
22.满冬梅,孔灵玲,等.子宫内膜异位症患者血清 MMP-9,和TIMP-1水平变化及意义:山东医药:2007,47(24):39.
23.Collette T,Bellehumeur c,Kats R,et al.Evidence for an increased release of proteolytie activity by the eutopie endometrial tissue in women with endometriosis and for involvement of marx metalloprotei · nase-9[J].Hum Reprod,2004,19(6):1257-1264.
24.ColletteT,MaheuxR,Mailloux J,et al.Increased expression ofmatrix met.d110pr0teinase-9 in the cutopic endometrial tissue of women with endometriosis[J].Hum Reprod,2006,.21(12):3059-3067.
25.DekkerGA.Etiology andpathogenesis of preeclampsia:Current Concepts[J].Am j Obstet Gyneco1.1998.179(5):1359-1375.
26.全围孕产妇死亡监测研究协作组.全国孕产妇死亡监测结果分析[J].中华妇产科杂志,1994.29(5):514-517.
27.Denis 1,J.Verweij J.Marx metrolloproteinase inhibitors:present achievements and future prospects[J].Invest New Drugs,1997.15(3):175-185.
28.马军花。于芹芹.Ⅳ型胶原、MMP-2及TIMP-2在妊高征胎盘组织中的表达及意义.山东医药:2007.11(47):45-46.
29.Boag AH,Young ID.Increased expression of the 72-kDa type Ⅳ collagenase in prostatic adenocarcinoma:demonstration by immunohistochemistry and in situ hybridization.Am J Pathol,1994:144:585-591.
30.Stearns ME,Stearns M.Immunohistochemical studies of activated matrix metalloproteinase-2(MMP-2 α ) expression in,human prostate cancer.Oncol Res,1996;8:63-67.
31.Wilson MJ,Norris H,Kapoor D et al.Gelatinalytic and caseinolytic proteinase activities in human prostatic secretions.J Urol,1993:149:653-658.
32.Festuccia C,Bologna M,Vicentini C et al.Increased matrix metalloproteinase-9secreation in short-term tissue cultures of prostatic tumor cells.Int J Cancer,1996:69:386-393.
33.Jung K,Nowak L,Lein M et al.Matrix metalloproteinase 1 and 3,,tissue inhibitor on metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer.Int J Cancer,1997:74:220-223.
34.Gohji K,Fujimoto N,Hara I et al.Serum matrix metalloproteinase-2 and its density in men with prostatic cancer as a new predictor of disease extension.Int J Cancer,1998:79:96-101.
35.Karayama H,Yokota K,Kurokawa Y et al.Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.Cancer,1998:82:1359-1366,
36.Dives B,Waxman J,Wasan Het al.Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion.Cancer Res,1993:53:5365-5369.
37.Gohji K,Fujimoto N,Ohkawa J.Imbalance between serum matrix metallproteinase-2and its inhibitor as a predictor of recurrence of urothelial cancer.Cancer Res,1998:77:650-655.
38.Gohji K,Fujimoto N,Komiyama T.Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors recurrence in patients with urothelial carcinoma.Cancer,1998:78:2379-2388.
39.Nakoman C,Resmi H,Ay O,et al.Effects ofbasic fibroblast factor(bFGF) on MMP 2,TIMP2and typeⅠ collagen levels in human lung carcinoma fibroblasts[J].Biochimie,2005,87(3-4):343-351.
40.Seo DW,Li H,Guedez L,et al.TIMP 2 mediated inhibition of angiogenesis:An MMPindependent mechanism[J].Cell,2003,114(2):171-180.
41.Fang J,Shing Y,Wiederschain D,et al.Matrix metalloproteinase 2 is required for the switch to the angiogenic phenotype in a tumor model[J].Proc Natl Acad Sci USA,2000,97(8):3884-3889.
42.Cho NH,Hong KP,Hong SH,et al.MMP expression profiling in recurred stage IB lung cancer[J].Oncogene,2004,23(3):845-851.
43.D'Agostino P,Camemi AR,Caruso R,et al.Matrix metalloproteinases production in malignant pleura1 effusions after talc pleurodesis[J].Clin Exp Immunol,2003,134(1):138-142.
44.王新允,杨菊红,马莹,等.肺癌MMPs和TIMPs的表达及浸润转移的研究[J].中国肺癌杂志, 2003,6(4):278-282.
45. Yang SF, Hsieh YS, Lin CL, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase 9 in nonsmall cell lung cancer patients(J).Clin Chim Acta, 2005, 354(1/2):91-99.
46. Heslin MJ, Yan J, Johnson MR, Weiss H, Diasio RB, Urist MM. Role of matrix metalloproteinases in colorectal carcinogenesis. Ann Surg 2001;233:786-792.
47.Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M, Leco K, Chamberlain D,Shepherd FA. Expression and prognostce significanic of metal loproteinases and their tissue inhibitors in patients with small-ceil lung cancer. J Clin Oncol 1999; 17:1802-1808.
48. Westermarck J, Kahari VM. Regulation of matrix metal loproteinase expression in tumor invasion. FASEB J 1999; 13:781-792.
49. Li XH, Zhang GY, Luo FJ, Xu MH, Li Q. Influence of expression of matrix metalloproteinase induced by H pylori infection in gastric cancer cell line. Shijie Huaren Xiaohua Zhazi 2003;11:544-546.
50. Sun JM, Zheng HC, Yang XF, Xin Y, Zhang YC. Relationship between expression of matrix metalloproteinase-7 and clinicopathobiological behaviors of gastric cancer. Shijie Huaren Xiaohua Zhazi 2003; 11:1310-1313.
51.Tao HQ, Zou SC, Wang RN, Lin YZ. Relationship between gastric carcinogenesis and angiogenesis. Shijie Huaren Xiaohua Zhazi 2003; 11:43-46.
52.Allgayer H, Babic R, Grutzner KU, Beyer BC, Tarabichi A, Schildberg FW, Heiss MM.Tumor-associated proteases and inhibitors in gastric cancer:analysis of prognostic impact and individual risk protease patters. Clin Exp Metastasis 1998;16:62-73.
53. Wang L, Zhang LH, Li YL, Li YL, Liu Z. Expression of MMP-9 and MMP-9 mRNA in gastric carcinoma and its correlation with angiogenesis. Zhonghua Yixue Zazhi 2003;83:782-786.
54. Monig SP, Baldus SE, Hennecken JK, Spiecker DB, Grass G, Schneider PM, Thiele J,Dienes HP, Holscher AH. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2001:39:597—602.
55. Kabashima A, Maehara Y, Kakeji Y, Baba H, Koga T, Sugimachi K. Clinicopahological features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin Cancer Res 2000;6:3581—3584.
56. Zhang S, Li L, Lin JY, Lin H. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloprote-inase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol 2003;9:899—904.
57. Shen KH, Chi CW, Lo SS, Kao HL, Lui WY, Wu CW. Serum matrix metal loproteinase-9 level associated with stromal reactin in patients with gastric cancer. Anticancer Res 2000;20:1307-1310.
58. Samantaray S, Sharma R, Chattopadhyaya TK, Gupta SD, Ralhan R. Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma.J Cancer Res Clin Oncol 2004;130:374-376.
59.Collinsl HM,Morris TM,Watson SA.Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer:relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase.Br J Cancer 2001;84:1664-1670.
60.Li L,Zhang S,Lin H,Lin JY.Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas.Aizheng 2002;21:305-310.
61.Sato F,ShimadaY,Watanabe G,Uchida S,MakinoT,Imamura M.Expression of vascular endothelial growth factor,matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer.Br J Cancer 1999;80:1366-1372.
62.Guo W,Ran Y,Wang G,Liu J,Yu L,Sun L,Yang Z.Expression and hypoxic regulation of vascular endothelial growth factor and matrix metalloproteinase-9 in esophageal carcinoma.Zhonghua Zhongliu Zazhi 2002;24:44-47.
63.Yamamoto H,Yinitketkumnuen A,Adachi Y,Taniguchi H,.Hirata T,Miyamoto N,Nosho K,Imsumran A,Fujita M,Hosokawa M,Hinoda Y,Imai K.Association of matrilysin-2(MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma.Carcinogenesis 2004;25:2353-2360.
64.Ohashi K,Nemoto T,Nakamura K,Nemori R.Increased expression of matrix metalloprotienase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas.Cancer 2000;88:2201-2209.
65.Forsyth PA,Wong H,Laing TD,Rewcastle NB,Morris DG,Muzik H,Leco KJ,Johnston RN,Brasher PM,Sutherland G,Edwards DR.Gelatinase-A(MMP-2),gelatinase-B(MMP-9)and membrane type matrix metalloproteinase-1(MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.Br J Cancer 1999;79:1828-1835.
66.刘栋才,杨竹林,李永.胆系恶性肿瘤MMP1和TIMP1表达及临床病理意义.中国现代医学杂志,2002:12(15):38-42.
67.Birkedal-Hansen B,Pavelic IP,Gluckman JL,et al,MMP and TIMP gene expression in head and neck squmous cell carcinomas an adjacent tissue.Oral Dis,2000:6:376-382.
68.Hara I,Miyake H,Hara S,et al.Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.J Vrol,2001:165:1769-1772.
69.Yamamoto FI.Itoh F,Jku S,et al.Expression of matrix metroproteinase and tissue inhibiitors of metalloproteineses in human pancreatic adencocearcinoma as clinicopathologic and prognostic significance of matrilysm expression.J Clin Oncol,2000:19:1118-1127.
70.连云宗,庄见良。等.MMPs/TIMPs在甲状腺乳头状癌细胞中的表达与作用的研究.2007年第15期.
71.gack s,vallon r,schmidt j,et al.exdivssion of interstitial collagenase during skeletal development of the mouse is restricted to osteoblast-like cells and hypertro phic chondrocytes[j].cell growth differ,1995,6(6):759.
72.Stricklin GP,Li LY,Nanney LB.Localization of mRNAs TIMP in healing porcine burn wounds[J].J Invest Dermatol,1994,103:352-358.
73.Wysocki AB,Staiano-Coico L,Grinnell F.Wound Fluid from chronic Leg Ulcers Contains Elevated Levels of Metalloproteinases MMP-2 and MMP-9[J].J Invest Dermatol,1993,101:64-68.
74.Lobmann R,Ambrosch A,Schultz G,et al.Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients[J].Diabetologia,2002,45(7):1011-1016.
75.Lateef H,Stevens MJ,Varani J.All-trans-retinoic acid suppresses matrix metalloproteinase activity and increases collagen synthesis in diabetic human skin in organ culture[J].Am J Pathol,2004,165(1):167-174.
76.Yager DR,Xhang LY,Liang HX,et al.Wound fluids from human prissure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids[J].J Invest Dermatol,1996,107:743-748.77.Sato H,Takino T,Okada Y,et al.A matrix metalloproteinase expressed on the surface of invasive tomour cells[J].Nature,1994,370(6484):61-65.
78.kusano k,miyaura c,inada m,et al.regulation of matrix metallop roteinases(mmp-2,-3,-9,and -13) by interleukin-1 and interleukin-6 in mouse calvaria:association of mmp induction with bone resorption[j].endocrino1,1998,139(3):1338.
79.pap t,pap g,hummel km,et al.membrane-type-1 matrix metalloprote inase is abundantly exdivssed in fibroblasts and osteoclasts at the bone-impiant interface of asepti cally loosened joint arthroplasties insitu[j].j rheumatol,1999,26(1):166.
80.rice dp,kim hj,thesleff i.detection of gelatinase b exdiyssion reveals osteoclastic bone resorption as a feature of early calvarial bone developme nt[j].bone,1997,21(6):479.
81.gazzerro e,rydziel s,canalis e,et al.skeletal bone morphogenetic proteins supdivss the exdivssion of collagenase-3 by rat osteoblasts[j].endocrinol,1999,140(2):562.
82.gazzerro e,rydziel s,canalis e,et al.skeletal bone morphogenetic proteins supdivss the exdivssion of collagenase-3 by rat osteoblasts[j].endocrinol,1999,140(2):562
83.Delany am,canalis e.dual regulation of stromelysin-3 by fibroblast growth factor-2in murine osteoblasts[j].j biol chem,1998,273(26):16595.
84.Fish JE,Peters SP.Airway remodeling and persistent airway obstruction in asthma[J].J Allergy Clin Immunol,1999,104(3 Pu 1):509-516.
85.Vignola AM,Riccobono L,Mirabella A,et al.Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis[J].Am J Respir Crit Care Med,1998,158(6):1945-1950.
86.Bosse M,Chakir J,Rouabhia M,.et al.Serum matrix metalloproteinase-9:Tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma[J].Am J Respir Crit Care Med.
87.Shah PK,Falk Badinom JJ.Humanmonocyte derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques:potential role of matrix degrading metalloproteinases and implications for plaque rupture[J].Circulation,1995,92(6):1565-1569.
88.Kai H,Ikeda H,Yasukawa H;et al.Peripheral blood levels of atrix Metalloproteases-2 and-9 are elevated in patients with acute coronary syndromes[J].JAm Coll Cardiol,1998,32(2):368-372.
89.Galis ZS,Khatri JJ.Matrix metalloproteinases in vascular remodeling and athergenesis:the good,the bad,and the ugly[J].Circ Res,2002,90(3):251-262.
90.蔡雪黎,张怀勤,等.血清MMP-9、TIMP-1和hs-CRP在急性冠脉综合征中的表达及临床意义[J].温州医学院学报,2007,3(37):215-217.
91.侯振江,张宗英.基质金属蛋白酶系统与恶性肿瘤[J].国外医学:临床生物化学与检验学分册,2004,25(1):23-25.
92.Di Girolamo N,Wakefield D,Coroneo MT.Differential expression of Matrix metallopmteinases and their tissue inhibitors at the advancing pterygium head[J].Invest Ophthalmol Vis Sci,2000,41(13):4142-4149.
93.Takahashi lt,Akiba K,Noguchi T,et al.Matrix metalloproteinase activity is enhanced during corneal wound repair in high glucose condition[J].Curt Eye Res,2000,21(2):608-615.
94.吴继红,徐萍,易苗英,等.体外培养的人视网膜母细胞瘤细胞株及其肿瘤血管生成相关因子表达的实验研究[J].中华眼科杂志,2005,41(5):419-422.
95.Bergers C,Brekken R,Mcmahon C,et al.Matrix metalloproteinasc-9 triggers the angiogenic switch during carcinogenesis[J].Nature Cell Biol,2000,2(10):737-744.
96.葛蓁。李玉军,刘波.MMP-9、TIMP-1和VEGF在视网膜母细胞瘤中的表达及意义[J].山东医药,19(47):53-55.
2.Menzies D,Ellis H.Intestinal obstruction from adhesions-how big is the problom?Ann R Coll Surg Engl 1990;72:60-63.
3.Ghosh AK.Factors involved in the regularion of type Ⅰ collagen gene expression:implication in fibrosisl[J]Exp Hiol Med(May-wood),2002,227(5):301-314.
4.何刚,刘生光,刘金新.凡丁糖预防腹膜粘连抑制胶原基因表达的实验研究[J].蚌埠医学院学报,2003,28(6):474-477.
5.Nagler A,Rivkind AI,Raphael J,et al.Halofuginone-an inhibi-tor of collagen type Ⅰ synthesis-prevents postoperative for-marion ofabdominal adhesions[J].Ann Su 1998,227(4):575-582.
6.袁发焕.MMPs、TIMPs与肾脏疾病.国外医学、泌尿系统分册1999,19(3):105.
7.Clegg PD,Burke RM,Coughlan AR,et al.Characterization of equine matrix metaIlo Droteinase2 and 9,and identification of the cellular sources of these enzymesin in joints.E--qine vet,1997,29:335-342.
8.Brand K.Cncer gene therapy with tissue inhibitors of metalloproteinase(TIMPs)[J].Curr GeneTher,2002:2(2):255.
9.Bassiouny HS.Song RH,HongXF,et al.Flow regulation of 72-kD eollagenase Ⅳ after experimental aterial injury.Circulation,1998,98:157-163.
10.Zhang B,wan MB,Wang LT,et al Expression of TIMP-1 and TGF-beta(1)mRNA in hepatic fibrosis rats and the therapeutic effects of Bushen Rougan Recipe 1[J]Zhong Xi Yi Jie He Xue Bao,2004,2(4):274-277.
11.Singh KP,Gerard HC,Hudson AP,et al.Dynamics of collagen MMP an d TIMP gene expression during the gran ulomatous,fi-brotic process induced by Schistosoma mansoni eggs[J].Ann Trop Med Parasitol,2004,98(6):581-593.
12.Menzies D.Peritoneal adhesions.Incidence,cause,and prevention.Surg Annu 1992;24(Pt 1):27-45.
13.Scott-Coombes D,Whawell S,Vipond MN,Thompson J.Human intraperitoneal fibrinolytic response to elective surgery.Br J Surg 1995;82:414-417.
14.Hellebrekers BW,Trimbos-Kemper GC,Bakkum EA,Trimbos JB,Declerck PJ,Kooistra T,Emeis JJ.Short-term effect of surgical trauma on rat peritoneal fibrinolytic activity and its role in adhesion formation.Thromb Haemost 2000;84:876-881.
15.Chegini N,Kotseos K,Bennett B,Diamond MP,Holmdahl L,Burns J.Matrix metalloproteinase(MMP-1) and tissue inhibitor of MMPin peritoneal fluids and sera and correlation with peritoneal adhesions.Fertil Steril 2001;76:1207-1211.
16.尚晓滨,吴成中,李东华,等.活血化瘀中药对清解通下中药增效作用的实验研究Ⅴ-粘连组 织中MMP-1和TIMP-1影响的实验研究.中国中西医结合外科杂志,2006,12(4):387.
1.Sato H,Takino T,Okada Y,et al.A matrix metalloproteinase expressed on the surface of invasive tumour cells[J].Nature,1994,370(6484):61-65.
2.Edwards DR,Beandry PP,Laing TD,et al.The roles of tissue inhibitors of metalloproteinases in tissue remodeling and cell growth[J].Int J of Obesity,1996,sg-s15,20 Suppl.
3.K1einer D,Stetler-Stevenson WG.Matrix metalloproteinase and metastasi[J].Cancer Chemother Phamacol,1999;43(suppl):42.
4.Brand K.Cncer gene therapy with tissue inhibitors of metalloproteinase(TIMPs)[J].Curr GeneTher,2002:2(2):255.
5.Springman E B,Angleton E L,Bikedalhansen H,et al Multiple modes of activation of latent human fibroblast collagenase evidence for the role of a cys-73 active-site zinc complex in latency and a cysteine swith mechanism for active ion[J].Proceedings of The National Academy of Sciences of The United States of America,1990;87(1):364-368.
6.Morgunova E,Tuuttila A,Bergmann U,et al.Structure of human pro-matrix metalloproteinase-2:active ion mechanism revealed[J].Science,1999;284(5420):1667-1670.
7.Sang Q X,Birkedal-Hansen H,Van Wart H E.Proteolytic and non-proteolytic Activation of human neutrophil progelatiase B[J].Biochimica and 8iophysica Acta,1995:1251(2):99-108.
8.Marcotte P A,Kozan I M,Dorwin S A,et al.The matrix metalloproteinase pump-1catalyzes formation of low-molecular-weight(?) urokinase in cultures of normal human kidney cells[J].Journal of Biological Chemistry,1992;267(20):13803-13806.
9.Edwards DR,Beandry PP,Laing TD,et al.The roles of tissue inhibitors of metalloproteinases in tissue remodeling and cell growth[J].Int J of Obesity,1996,S9-S15,20 Suppl.
10.Vaalamo M,Leivo T,Sarialho-kere U.Differential expression of tissue inhibitors of metalloproteinases(TIMP-1,2,3,and -4) in normal and aberrant wound healing[J].Hum Pathol,1999,30(7):795-802.
11.DeClerck YA,Dartll MI,Eeckhout Y,et al.Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2(TIMP-2)[J].Gene,1994,139:185-191.
12.Gaire M,Magbanul Z,McDonnell S,et al.Structure and expression of the human gene for the matrix metalloproteinase matrillysin[J].J Biol Chem,1994,269:2032-2040.
13.邵彬,聂青和.基质金属蛋白酶组织抑制剂(TIMPs)的基础及临床研究现状[J];实用肝脏病杂志:2005年03期.
14.李敬安,任星峰,等.慢性乙型肝炎肝组织Ⅰ,Ⅲ型胶原及MMP、TIMP的表达[J]中国医师 进修杂志:2006;5.
15.张健珍,龙英姿,等.慢性乙型肝炎血清MMP-1和TIMP-1与肝脏炎症及肝纤维化的相关性;中国实用内科杂志:2007年19期.
16.Kikkawa F,Nawa A,Tamakoshi S,et al.Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the ovary.Cancer,1998,82(11):2249-2255.
17.Tamakoshi K,Kikkawa F,Maeda O,et al.Hyaluronidase activity in gynaecological cancer tissue with different metastatic forms[J].Br J Cancer,1997,75:1807-1811.
18.Inoue Y,AbeK,ObataK,etal.Immunohistochemical Studies on matrixmetall oproteinase-2 MMP-9 and type Ⅳ collage in endometrial carcinoma J.J Obstet Gynecol Res,1997,23:139-145.
19.Davidson B,Goldberg I,Kopolvic J,et al.MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma a clinicopathologic study using immunohistochemistry and mRNA in situhybridization.Gynecol Oncol,1999,73(3):372-382.
20.Sang QX.Complex role of matrix metalloproteinases in angiogenes[J].Cell Res,1998,8(3):171-177.
21.Kim I,Kim HG,Moon SO,et al.Angiopoietin-1 induces endothe-lial cell sprouting through the activation of focal adhesion kinase and plasmin secretion[J].Circ Res,2000,86(9):952-959.
22.满冬梅,孔灵玲,等.子宫内膜异位症患者血清 MMP-9,和TIMP-1水平变化及意义:山东医药:2007,47(24):39.
23.Collette T,Bellehumeur c,Kats R,et al.Evidence for an increased release of proteolytie activity by the eutopie endometrial tissue in women with endometriosis and for involvement of marx metalloprotei · nase-9[J].Hum Reprod,2004,19(6):1257-1264.
24.ColletteT,MaheuxR,Mailloux J,et al.Increased expression ofmatrix met.d110pr0teinase-9 in the cutopic endometrial tissue of women with endometriosis[J].Hum Reprod,2006,.21(12):3059-3067.
25.DekkerGA.Etiology andpathogenesis of preeclampsia:Current Concepts[J].Am j Obstet Gyneco1.1998.179(5):1359-1375.
26.全围孕产妇死亡监测研究协作组.全国孕产妇死亡监测结果分析[J].中华妇产科杂志,1994.29(5):514-517.
27.Denis 1,J.Verweij J.Marx metrolloproteinase inhibitors:present achievements and future prospects[J].Invest New Drugs,1997.15(3):175-185.
28.马军花。于芹芹.Ⅳ型胶原、MMP-2及TIMP-2在妊高征胎盘组织中的表达及意义.山东医药:2007.11(47):45-46.
29.Boag AH,Young ID.Increased expression of the 72-kDa type Ⅳ collagenase in prostatic adenocarcinoma:demonstration by immunohistochemistry and in situ hybridization.Am J Pathol,1994:144:585-591.
30.Stearns ME,Stearns M.Immunohistochemical studies of activated matrix metalloproteinase-2(MMP-2 α ) expression in,human prostate cancer.Oncol Res,1996;8:63-67.
31.Wilson MJ,Norris H,Kapoor D et al.Gelatinalytic and caseinolytic proteinase activities in human prostatic secretions.J Urol,1993:149:653-658.
32.Festuccia C,Bologna M,Vicentini C et al.Increased matrix metalloproteinase-9secreation in short-term tissue cultures of prostatic tumor cells.Int J Cancer,1996:69:386-393.
33.Jung K,Nowak L,Lein M et al.Matrix metalloproteinase 1 and 3,,tissue inhibitor on metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer.Int J Cancer,1997:74:220-223.
34.Gohji K,Fujimoto N,Hara I et al.Serum matrix metalloproteinase-2 and its density in men with prostatic cancer as a new predictor of disease extension.Int J Cancer,1998:79:96-101.
35.Karayama H,Yokota K,Kurokawa Y et al.Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.Cancer,1998:82:1359-1366,
36.Dives B,Waxman J,Wasan Het al.Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion.Cancer Res,1993:53:5365-5369.
37.Gohji K,Fujimoto N,Ohkawa J.Imbalance between serum matrix metallproteinase-2and its inhibitor as a predictor of recurrence of urothelial cancer.Cancer Res,1998:77:650-655.
38.Gohji K,Fujimoto N,Komiyama T.Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors recurrence in patients with urothelial carcinoma.Cancer,1998:78:2379-2388.
39.Nakoman C,Resmi H,Ay O,et al.Effects ofbasic fibroblast factor(bFGF) on MMP 2,TIMP2and typeⅠ collagen levels in human lung carcinoma fibroblasts[J].Biochimie,2005,87(3-4):343-351.
40.Seo DW,Li H,Guedez L,et al.TIMP 2 mediated inhibition of angiogenesis:An MMPindependent mechanism[J].Cell,2003,114(2):171-180.
41.Fang J,Shing Y,Wiederschain D,et al.Matrix metalloproteinase 2 is required for the switch to the angiogenic phenotype in a tumor model[J].Proc Natl Acad Sci USA,2000,97(8):3884-3889.
42.Cho NH,Hong KP,Hong SH,et al.MMP expression profiling in recurred stage IB lung cancer[J].Oncogene,2004,23(3):845-851.
43.D'Agostino P,Camemi AR,Caruso R,et al.Matrix metalloproteinases production in malignant pleura1 effusions after talc pleurodesis[J].Clin Exp Immunol,2003,134(1):138-142.
44.王新允,杨菊红,马莹,等.肺癌MMPs和TIMPs的表达及浸润转移的研究[J].中国肺癌杂志, 2003,6(4):278-282.
45. Yang SF, Hsieh YS, Lin CL, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase 9 in nonsmall cell lung cancer patients(J).Clin Chim Acta, 2005, 354(1/2):91-99.
46. Heslin MJ, Yan J, Johnson MR, Weiss H, Diasio RB, Urist MM. Role of matrix metalloproteinases in colorectal carcinogenesis. Ann Surg 2001;233:786-792.
47.Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M, Leco K, Chamberlain D,Shepherd FA. Expression and prognostce significanic of metal loproteinases and their tissue inhibitors in patients with small-ceil lung cancer. J Clin Oncol 1999; 17:1802-1808.
48. Westermarck J, Kahari VM. Regulation of matrix metal loproteinase expression in tumor invasion. FASEB J 1999; 13:781-792.
49. Li XH, Zhang GY, Luo FJ, Xu MH, Li Q. Influence of expression of matrix metalloproteinase induced by H pylori infection in gastric cancer cell line. Shijie Huaren Xiaohua Zhazi 2003;11:544-546.
50. Sun JM, Zheng HC, Yang XF, Xin Y, Zhang YC. Relationship between expression of matrix metalloproteinase-7 and clinicopathobiological behaviors of gastric cancer. Shijie Huaren Xiaohua Zhazi 2003; 11:1310-1313.
51.Tao HQ, Zou SC, Wang RN, Lin YZ. Relationship between gastric carcinogenesis and angiogenesis. Shijie Huaren Xiaohua Zhazi 2003; 11:43-46.
52.Allgayer H, Babic R, Grutzner KU, Beyer BC, Tarabichi A, Schildberg FW, Heiss MM.Tumor-associated proteases and inhibitors in gastric cancer:analysis of prognostic impact and individual risk protease patters. Clin Exp Metastasis 1998;16:62-73.
53. Wang L, Zhang LH, Li YL, Li YL, Liu Z. Expression of MMP-9 and MMP-9 mRNA in gastric carcinoma and its correlation with angiogenesis. Zhonghua Yixue Zazhi 2003;83:782-786.
54. Monig SP, Baldus SE, Hennecken JK, Spiecker DB, Grass G, Schneider PM, Thiele J,Dienes HP, Holscher AH. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2001:39:597—602.
55. Kabashima A, Maehara Y, Kakeji Y, Baba H, Koga T, Sugimachi K. Clinicopahological features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin Cancer Res 2000;6:3581—3584.
56. Zhang S, Li L, Lin JY, Lin H. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloprote-inase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol 2003;9:899—904.
57. Shen KH, Chi CW, Lo SS, Kao HL, Lui WY, Wu CW. Serum matrix metal loproteinase-9 level associated with stromal reactin in patients with gastric cancer. Anticancer Res 2000;20:1307-1310.
58. Samantaray S, Sharma R, Chattopadhyaya TK, Gupta SD, Ralhan R. Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma.J Cancer Res Clin Oncol 2004;130:374-376.
59.Collinsl HM,Morris TM,Watson SA.Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer:relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase.Br J Cancer 2001;84:1664-1670.
60.Li L,Zhang S,Lin H,Lin JY.Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas.Aizheng 2002;21:305-310.
61.Sato F,ShimadaY,Watanabe G,Uchida S,MakinoT,Imamura M.Expression of vascular endothelial growth factor,matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer.Br J Cancer 1999;80:1366-1372.
62.Guo W,Ran Y,Wang G,Liu J,Yu L,Sun L,Yang Z.Expression and hypoxic regulation of vascular endothelial growth factor and matrix metalloproteinase-9 in esophageal carcinoma.Zhonghua Zhongliu Zazhi 2002;24:44-47.
63.Yamamoto H,Yinitketkumnuen A,Adachi Y,Taniguchi H,.Hirata T,Miyamoto N,Nosho K,Imsumran A,Fujita M,Hosokawa M,Hinoda Y,Imai K.Association of matrilysin-2(MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma.Carcinogenesis 2004;25:2353-2360.
64.Ohashi K,Nemoto T,Nakamura K,Nemori R.Increased expression of matrix metalloprotienase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas.Cancer 2000;88:2201-2209.
65.Forsyth PA,Wong H,Laing TD,Rewcastle NB,Morris DG,Muzik H,Leco KJ,Johnston RN,Brasher PM,Sutherland G,Edwards DR.Gelatinase-A(MMP-2),gelatinase-B(MMP-9)and membrane type matrix metalloproteinase-1(MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.Br J Cancer 1999;79:1828-1835.
66.刘栋才,杨竹林,李永.胆系恶性肿瘤MMP1和TIMP1表达及临床病理意义.中国现代医学杂志,2002:12(15):38-42.
67.Birkedal-Hansen B,Pavelic IP,Gluckman JL,et al,MMP and TIMP gene expression in head and neck squmous cell carcinomas an adjacent tissue.Oral Dis,2000:6:376-382.
68.Hara I,Miyake H,Hara S,et al.Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.J Vrol,2001:165:1769-1772.
69.Yamamoto FI.Itoh F,Jku S,et al.Expression of matrix metroproteinase and tissue inhibiitors of metalloproteineses in human pancreatic adencocearcinoma as clinicopathologic and prognostic significance of matrilysm expression.J Clin Oncol,2000:19:1118-1127.
70.连云宗,庄见良。等.MMPs/TIMPs在甲状腺乳头状癌细胞中的表达与作用的研究.2007年第15期.
71.gack s,vallon r,schmidt j,et al.exdivssion of interstitial collagenase during skeletal development of the mouse is restricted to osteoblast-like cells and hypertro phic chondrocytes[j].cell growth differ,1995,6(6):759.
72.Stricklin GP,Li LY,Nanney LB.Localization of mRNAs TIMP in healing porcine burn wounds[J].J Invest Dermatol,1994,103:352-358.
73.Wysocki AB,Staiano-Coico L,Grinnell F.Wound Fluid from chronic Leg Ulcers Contains Elevated Levels of Metalloproteinases MMP-2 and MMP-9[J].J Invest Dermatol,1993,101:64-68.
74.Lobmann R,Ambrosch A,Schultz G,et al.Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients[J].Diabetologia,2002,45(7):1011-1016.
75.Lateef H,Stevens MJ,Varani J.All-trans-retinoic acid suppresses matrix metalloproteinase activity and increases collagen synthesis in diabetic human skin in organ culture[J].Am J Pathol,2004,165(1):167-174.
76.Yager DR,Xhang LY,Liang HX,et al.Wound fluids from human prissure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids[J].J Invest Dermatol,1996,107:743-748.77.Sato H,Takino T,Okada Y,et al.A matrix metalloproteinase expressed on the surface of invasive tomour cells[J].Nature,1994,370(6484):61-65.
78.kusano k,miyaura c,inada m,et al.regulation of matrix metallop roteinases(mmp-2,-3,-9,and -13) by interleukin-1 and interleukin-6 in mouse calvaria:association of mmp induction with bone resorption[j].endocrino1,1998,139(3):1338.
79.pap t,pap g,hummel km,et al.membrane-type-1 matrix metalloprote inase is abundantly exdivssed in fibroblasts and osteoclasts at the bone-impiant interface of asepti cally loosened joint arthroplasties insitu[j].j rheumatol,1999,26(1):166.
80.rice dp,kim hj,thesleff i.detection of gelatinase b exdiyssion reveals osteoclastic bone resorption as a feature of early calvarial bone developme nt[j].bone,1997,21(6):479.
81.gazzerro e,rydziel s,canalis e,et al.skeletal bone morphogenetic proteins supdivss the exdivssion of collagenase-3 by rat osteoblasts[j].endocrinol,1999,140(2):562.
82.gazzerro e,rydziel s,canalis e,et al.skeletal bone morphogenetic proteins supdivss the exdivssion of collagenase-3 by rat osteoblasts[j].endocrinol,1999,140(2):562
83.Delany am,canalis e.dual regulation of stromelysin-3 by fibroblast growth factor-2in murine osteoblasts[j].j biol chem,1998,273(26):16595.
84.Fish JE,Peters SP.Airway remodeling and persistent airway obstruction in asthma[J].J Allergy Clin Immunol,1999,104(3 Pu 1):509-516.
85.Vignola AM,Riccobono L,Mirabella A,et al.Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis[J].Am J Respir Crit Care Med,1998,158(6):1945-1950.
86.Bosse M,Chakir J,Rouabhia M,.et al.Serum matrix metalloproteinase-9:Tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma[J].Am J Respir Crit Care Med.
87.Shah PK,Falk Badinom JJ.Humanmonocyte derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques:potential role of matrix degrading metalloproteinases and implications for plaque rupture[J].Circulation,1995,92(6):1565-1569.
88.Kai H,Ikeda H,Yasukawa H;et al.Peripheral blood levels of atrix Metalloproteases-2 and-9 are elevated in patients with acute coronary syndromes[J].JAm Coll Cardiol,1998,32(2):368-372.
89.Galis ZS,Khatri JJ.Matrix metalloproteinases in vascular remodeling and athergenesis:the good,the bad,and the ugly[J].Circ Res,2002,90(3):251-262.
90.蔡雪黎,张怀勤,等.血清MMP-9、TIMP-1和hs-CRP在急性冠脉综合征中的表达及临床意义[J].温州医学院学报,2007,3(37):215-217.
91.侯振江,张宗英.基质金属蛋白酶系统与恶性肿瘤[J].国外医学:临床生物化学与检验学分册,2004,25(1):23-25.
92.Di Girolamo N,Wakefield D,Coroneo MT.Differential expression of Matrix metallopmteinases and their tissue inhibitors at the advancing pterygium head[J].Invest Ophthalmol Vis Sci,2000,41(13):4142-4149.
93.Takahashi lt,Akiba K,Noguchi T,et al.Matrix metalloproteinase activity is enhanced during corneal wound repair in high glucose condition[J].Curt Eye Res,2000,21(2):608-615.
94.吴继红,徐萍,易苗英,等.体外培养的人视网膜母细胞瘤细胞株及其肿瘤血管生成相关因子表达的实验研究[J].中华眼科杂志,2005,41(5):419-422.
95.Bergers C,Brekken R,Mcmahon C,et al.Matrix metalloproteinasc-9 triggers the angiogenic switch during carcinogenesis[J].Nature Cell Biol,2000,2(10):737-744.
96.葛蓁。李玉军,刘波.MMP-9、TIMP-1和VEGF在视网膜母细胞瘤中的表达及意义[J].山东医药,19(47):53-55.